热门资讯> 正文

Pacira在将2025年收入调整至低于共识后股价下跌

2026-01-09 06:49

Pacira生物科学(PCRX) 0

Pacira BioSciences (PCRX) is down ~10% in after-hours trading Thursday after revising downwards its expectation for 2025 total revenues.
The company reported preliminary full-year revenues of $726.4M. Consensus is $730.22M.
Pacira also noted that during Q4, it repurchased 2M shares in the open market for $50M.

More on Pacira BioSciences

Pacira BioSciences, Inc. 2025 Q3 - Results - Earnings Call Presentation
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences: Generics Are Coming For The Crown Jewel
Pacira reports preliminary FY25 revenue of $726.4M
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。